The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
Alzheimer’s Disease Market is primarily driven by a rising geriatric population, who are more prone to neurodegenerative disorders. In over 90% of patients with Alzheimer’s, symptoms do not appear till the age 60. Furthermore, incidence of the disease rises with age and doubles every 5 years after age 65. In addition to the rising ageing population, Alzheimer’s disease market is also driven by improving diagnosis and drug treatment rates which includes a rising adoption of newer diagnostic techniques for early diagnosis. Furthermore, the ongoing development of several novel therapeutics that have a strong safety and efficacy profile is also expected to catalyse the growth of the market in the coming years.
Alzheimer's Disease (AD) refers to a neurodegenerative disorder characterized by the degeneration of nerve cells in several areas of the brain that control thought, memory, and language. The most common symptoms include memory impairment, depression, loss of inhibitions, etc. As the disease progresses, symptoms may include issues with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral problems. Alzheimer’s disease currently represents the seventh leading cause of death among all diseases and one of the biggest causes of disability and dependency among the geriatric population. Alzheimer’s disease has physical, psychological, social, and economic impacts, not only for individuals living with the disease, but also for their carers, families, and society at large.
IMARC Group’s new report "Alzheimer’s Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast" provides an exhaustive analysis of the Alzheimer’s Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Alzheimer’s Disease market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Alzheimer’s Disease across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Alzheimer’s Disease and also represents the largest market for Alzheimer’s Disease treatment. Furthermore, the current Alzheimer’s Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Alzheimer’s Disease market in any manner.
Time Period of the Study
This report also provides a detailed analysis of the current Alzheimer’s Disease marketed drugs and late-stage pipeline drugs.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at